Enhanced NF-κB activity impairs vascular function through PARP-1-, SP-1-, and COX-2-dependent mechanisms in type 2 diabetes

Diabetes

Volumn 62, Issue 6, 2013, Pages 2078-2087

  Kassan, Modar ^a,b   Choi, Soo Kyoung ^a   Galán, Maria ^a,b   Bishop, Alexander ^c   Umezawa, Kazuo ^d   Trebak, Mohamed ^e   Belmadani, Souad ^b   Matrougui, Khalid ^a,b  

^a TULANE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Eastern Virginia School of Medicine   (United States)

^c Mays Cancer Center at UT Health San Antonio   (United States)

^d KEIO UNIVERSITY   (Japan)

^e ALBANY MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLESTEROL; CYCLOOXYGENASE 2; ENDOTHELIAL NITRIC OXIDE SYNTHASE; GLUCOSE; I KAPPA B; INSULIN; INTERLEUKIN 6; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE 1; TRANSCRIPTION FACTOR RELA; TRANSCRIPTION FACTOR SP1; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTERY RESISTANCE; ARTICLE; BODY WEIGHT; CARDIOVASCULAR FUNCTION; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; CORONARY ARTERY; DOWN REGULATION; ENDOTHELIUM CELL; ENZYME ACTIVITY; ENZYME INHIBITION; GLUCOSE BLOOD LEVEL; IN VITRO STUDY; INSULIN BLOOD LEVEL; MALE; MESENTERIC ARTERY; MOUSE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; SYSTOLIC BLOOD PRESSURE;

ANIMALS; BENZAMIDES; CELLS, CULTURED; CYCLOHEXANONES; CYCLOOXYGENASE 2; DIABETES MELLITUS, TYPE 2; ENDOTHELIAL CELLS; MALE; MICE; NF-KAPPA B; POLY(ADP-RIBOSE) POLYMERASES; REAL-TIME POLYMERASE CHAIN REACTION; SP1 TRANSCRIPTION FACTOR;

EID: 84878250579     PISSN: 00121797     EISSN: 1939327X     Source Type: Journal    
DOI: 10.2337/db12-1374     Document Type: Article

References (48)

1. Ruderman NB, Williamson JR, Brownlee M. Glucose and diabetic vascular disease. FASEB J 1992;6:2905-2914
2. Cosentino F, Lüscher TF. Endothelial dysfunction in diabetes mellitus. J Cardiovasc Pharmacol 1998;32(Suppl. 3):S54-S61 (Pubitemid 29019754)
3. Cai S, Khoo J, Mussa S, Alp NJ, Channon KM. Endothelial nitric oxide synthase dysfunction in diabetic mice: importance of tetrahydrobiopterin in eNOS dimerisation. Diabetologia 2005;48:1933-1940 (Pubitemid 41317851)
4. Hadi HA, Suwaidi JA. Endothelial dysfunction in diabetes mellitus. Vasc Health Risk Manag 2007;3:853-876
5. Ding H, Triggle CR. Endothelial cell dysfunction and the vascular complications associated with type 2 diabetes: assessing the health of the endothelium. Vasc Health Risk Manag 2005;1:55-71
6. Yang G, Lucas R, Caldwell R, Yao L, Romero MJ, Caldwell RW. Novel mechanisms of endothelial dysfunction in diabetes. J Cardiovasc Dis Res 2010;1:59-63
7. Creager MA, Lüscher TF, Cosentino F, Beckman JA. Diabetes and vascular disease: pathophysiology, clinical consequences, and medical therapy: Part I. Circulation 2003;108:1527-1532 (Pubitemid 37176462)
8. Harrison DG. Cellular and molecular mechanisms of endothelial cell dysfunction. J Clin Invest 1997;100:2153-2157 (Pubitemid 27500136)
9. Yang Z, Ming XF. Recent advances in understanding endothelial dysfunction in atherosclerosis. Clin Med Res 2006;4:53-65
10. Guijarro C, Egido J. Transcription factor-kappa B (NF-kappa B) and renal disease. Kidney Int 2001;59:415-424 (Pubitemid 32157906)
11. Shanmugam N, Gaw Gonzalo IT, Natarajan R. Molecular mechanisms of high glucose-induced cyclooxygenase-2 expression in monocytes. Diabetes 2004;53:795-802 (Pubitemid 38270651)
12. Crofford LJ, Tan B, McCarthy CJ, Hla T. Involvement of nuclear factor kappa B in the regulation of cyclooxygenase-2 expression by interleukin-1 in rheumatoid synoviocytes. Arthritis Rheum 1997;40:226-236 (Pubitemid 27114086)
13. Charalambous MP, Lightfoot T, Speirs V, Horgan K, Gooderham NJ. Expression of COX-2, NF-kappaB-p65, NF-kappaB-p50 and IKKalpha in malignant and adjacent normal human colorectal tissue. Br J Cancer 2009;101:106-115
14. Hassa PO, Haenni SS, Buerki C, et al. Acetylation of poly(ADP-ribose) polymerase-1 by p300/CREB-binding protein regulates coactivation of NF-kappaB-dependent transcription. J Biol Chem 2005;280:40450-40464 (Pubitemid 41780532)
15. Choi SK, Galán M, Kassan M, Partyka M, Trebak M, Matrougui K. Poly (ADP-ribose) polymerase 1 inhibition improves coronary arteriole function in type 2 diabetes mellitus. Hypertension 2012;59:1060-1068
16. Oliver FJ, Ménissier-de Murcia J, Nacci C, et al. Resistance to endotoxic shock as a consequence of defective NF-kappaB activation in poly (ADPribose) polymerase-1 deficient mice. EMBO J 1999;18:4446-4454 (Pubitemid 29391254)
17. Hassa PO, Hottiger MO. A role of poly (ADP-ribose) polymerase in NFkappaB transcriptional activation. Biol Chem 1999;380:953-959 (Pubitemid 29412755)
18. Choi SK, Galán M, Partyka M, Trebak M, Belmadani S, Matrougui K. Chronic inhibition of epidermal growth factor receptor tyrosine kinase and extracellular signal-regulated kinases 1 and 2 (ERK1/2) augments vascular response to limb ischemia in type 2 diabetic mice. Am J Pathol 2012;180:410-418
19. Kassan M, Galan M, Partyka M, Trebak M, Matrougui K. Interleukin-10 released by CD4(+)CD25(+) natural regulatory T cells improves microvascular endothelial function through inhibition of NADPH oxidase activity in hypertensive mice. Arterioscler Thromb Vasc Biol 2011;31:2534-2542
20. Amin AH, Abd Elmageed ZY, Partyka M, Matrougui K. Mechanisms of myogenic tone of coronary arteriole: Role of down stream signaling of the EGFR tyrosine kinase. Microvasc Res 2011;81:135-142
21. Schalkwijk CG, Stehouwer CD. Vascular complications in diabetes mellitus: the role of endothelial dysfunction. Clin Sci (Lond) 2005;109:143-159 (Pubitemid 41117297)
22. Maser RE, Mitchell BD, Vinik AI, Freeman R. The association between cardiovascular autonomic neuropathy and mortality in individuals with diabetes: a meta-analysis. Diabetes Care 2003;26:1895-1901 (Pubitemid 36929140)
23. Laing SP, Swerdlow AJ, Slater SD, et al. Mortality from heart disease in a cohort of 23,000 patients with insulin-treated diabetes. Diabetologia 2003;46:760-765 (Pubitemid 36831403)
24. Haffner SM, Lehto S, Rönnemaa T, Pyörälä K, Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 1998;339:229-234 (Pubitemid 28350165)
25. Gutterman DD. Vascular dysfunction in hyperglycemia: is protein kinase C the culprit? Circ Res 2002;90:5-7 (Pubitemid 34074599)
26. Sánchez A, Contreras C, Martínez P, et al. Enhanced cyclooxygenase 2-mediated vasorelaxation in coronary arteries from insulin-resistant obese Zucker rats. Atherosclerosis 2010;213:392-399
27. Schuhmacher S, Oelze M, Bollmann F, et al. Vascular dysfunction in experimental diabetes is improved by pentaerithrityl tetranitrate but not isosorbide-5-mononitrate therapy. Diabetes 2011;60:2608-2616
28. Natali A, Toschi E, Baldeweg S, et al. Clustering of insulin resistance with vascular dysfunction and low-grade inflammation in type 2 diabetes. Diabetes 2006;55:1133-1140 (Pubitemid 44100192)
29. Lorenzo O, Picatoste B, Ares-Carrasco S, et al. Potential role of nuclear factor κB in diabetic cardiomyopathy. Mediators Inflamm 2011;2011:652097.
30. Rodríguez-Ayala E, Anderstam B, Suliman ME, et al. Enhanced RAGE-mediated NFkappaB stimulation in in flamed hemodialysis patients. Atherosclerosis 2005;180:333-340 (Pubitemid 41072904)
31. Scotland RS, Chauhan S, Vallance PJ, Ahluwalia A. An endothelium-derived hyperpolarizing factor-like factor moderates myogenic constriction of mesenteric resistance arteries in the absence of endothelial nitric oxide synthase-derived nitric oxide. Hypertension 2001;38:833-839 (Pubitemid 34258679)
32. Bagi Z. Mechanisms of coronary microvascular adaptation to obesity. Am J Physiol Regul Integr Comp Physiol 2009;297:R556-R567
33. Picchi A, Capobianco S, Qiu T, et al. Coronary microvascular dysfunction in diabetes mellitus: A review. World J Cardiol 2010;2:377-390
34. Belmadani S, Palen DI, Gonzalez-Villalobos RA, Boulares HA, Matrougui K. Elevated epidermal growth factor receptor phosphorylation induces resistance artery dysfunction in diabetic db/db mice. Diabetes 2008;57:1629-1637
35. Lagaud GJ, Masih-Khan E, Kai S, van Breemen C, Dubé GP. Influence of type II diabetes on arterial tone and endothelial function in murine mesenteric resistance arteries. J Vasc Res 2001;38:578 -589
36. Moncada S, Higgs A. The L-arginine-nitric oxide pathway. N Engl J Med 1993;329:2002-2012 (Pubitemid 24015045)
37. Palen DI, Matrougui K. Role of elevated EGFR phosphorylation in the induction of structural remodelling and altered mechanical properties of resistance artery from type 2 diabetic mice. Diabetes Metab Res Rev 2008;24:651-656
38. Su J, Lucchesi PA, Gonzalez-Villalobos RA, et al. Role of advanced glycation end products with oxidative stress in resistance artery dysfunction in type 2 diabetic mice. Arterioscler Thromb Vasc Biol 2008;28:1432-1438
39. Zeiher AM, Fisslthaler B, Schray-Utz B, Busse R. Nitric oxide modulates the expression of monocyte chemoattractant protein 1 in cultured human endothelial cells. Circ Res 1995;76:980-986
40. Lee MY, Wang Y, Vanhoutte PM. Senescence of cultured porcine coronary arterial endothelial cells is associated with accelerated oxidative stress and activation of NFkB. J Vasc Res 2010;47:287-298
41. Zerfaoui M, Errami Y, Naura AS, et al. Poly(ADP-ribose) polymerase-1 is a determining factor in Crm1-mediated nuclear export and retention of p65 NF-kappa B upon TLR4 stimulation. J Immunol 2010;185:1894-1902
42. Ménissier de Murcia J, Ricoul M, Tartier L, et al. Functional interaction between PARP-1 and PARP-2 in chromosome stability and embryonic development in mouse. EMBO J 2003;22:2255-2263 (Pubitemid 36565548)
43. Kumar S, Sun X, Wiseman DA, et al. Hydrogen peroxide decreases endothelial nitric oxide synthase promoter activity through the inhibition of Sp1 activity. DNA Cell Biol 2009;28:119-129
44. Benjamin JT, Carver BJ, Plosa EJ, et al. NF-kappaB activation limits airway branching through inhibition of Sp1-mediated fibroblast growth factor-10 expression. J Immunol 2010;185:4896-4903
45. Bagi Z, Erdei N, Toth A, et al. Type 2 diabetic mice have increased arteriolar tone and blood pressure: enhanced release of COX-2-derived constrictor prostaglandins. Arterioscler Thromb Vasc Biol 2005;25:1610 -1616
46. Zhang J, Lei T, Chen X, et al. Resistin up-regulates COX-2 expression via TAK1-IKK-NF-kappaB signaling pathway. Inflammation 2010;33:25-33
47. Hippisley-Cox J, Coupland C. Risk of myocardial infarction in patients taking cyclo-oxygenase-2 inhibitors or conventional non-steroidal anti-inflammatory drugs: population based nested case-control analysis. BMJ 2005;330:1366-1372
48. Bäck M, Yin L, Ingelsson E. Cyclooxygenase-2 inhibitors and cardiovascular risk in a nation-wide cohort study after the withdrawal of rofecoxib. Eur Heart J 2012;33:1928-1933